Cargando…
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
BACKGROUND: The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in castration-resistant prostate cancer (CRPC). However, no study has examined the prognostic value of NLR and PLR in the context of CTCs. METHODS...
Autores principales: | Chong, Weelic, Zhang, Zhenchao, Luo, Rui, Gu, Jian, Lin, Jianqing, Wei, Qiang, Li, Bingshan, Myers, Ronald, Lu-Yao, Grace, Kelly, William Kevin, Wang, Chun, Yang, Hushan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170812/ https://www.ncbi.nlm.nih.gov/pubmed/34078304 http://dx.doi.org/10.1186/s12885-021-08405-3 |
Ejemplares similares
-
Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Wang, Chun, et al.
Publicado: (2021) -
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism
por: Abu-Khalaf, Maysa, et al.
Publicado: (2022) -
Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as
prognostic markers in patients with metastatic castration-resistant prostate
cancer
por: Meisel, Alexander, et al.
Publicado: (2022) -
Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
por: Sundar, Santhanam, et al.
Publicado: (2015) -
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)